Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus and myositis are now recruiting.
Quarterly report pursuant to Section 13 or 15(d)
Current report filing
Definitive proxy statements
View and filter by group or type